Hiperlipidemia e intolerancia a la glucosa en un grupo de pacientes infectados con VIH que reciben terapia antirretrovírica hiperactiva Hyperlipidemia and glucose intolerance in patients with HIV infection receiving antiretroviral therapy - Carlos José Castro-Sansores; Adrián Santos-Rivero; Dora Lara-Perera; Pedro González-Martínez; Gabriela Alonso-Salomón; Renan A. Góngora-Biachi (Instituto Nacional de Salud Pública, 2006)
OBJETIVO: Determinar la prevalencia de los efectos secundarios sobre el metabolismo de los lípidos y la glucosa provocados por la terapia antirretrovírica hiperactiva (TARHA), así como el impacto que el uso de los distintos esquemas de antirretrovíricos tiene sobre los lípidos y la glucosa en un grupo de pacientes de Yucatán, México. MATERIAL Y MÉTODOS: Se realizó un estudio transversal. A cada paciente se le aplicó un cuestionario creado para este estudio y se le determinaron los valores de colesterol total, triglicéridos y glucosa en ayuno. Se determinó la prevalencia de hiperlipidemia y alteraciones de la glucosa y su relación con las variables de la encuesta RESULTADOS: Se estudiaron 211 pacientes, 36 (17%) mujeres y 175 (83%) hombres; 92 (44%) tuvieron hiperlipidemia. De éstos, 43 (20%) presentaron hipercolesterolemia (HC) y 82 (39%) hipertrigliceridemia (HT). La presencia de HC e HT combinadas se verificó en 30 (14%) pacientes; además, 19 (9%) pacientes exhibieron alteraciones en la glucosa, seis (3%) presentaron diabetes mellitus y 13 (6%), intolerancia a la glucosa. Las variables que se vincularon con la presencia de hiperlipidemia fueron los números de linfocitos CD4 >350 células/µl [RM= 2.79 (1.08-7.27), p= 0.03], el género masculino [RM= 3.6 (1.4-9.12), p= 0.006] y el uso de nucleósidos inhibidores de la transcriptasa inversa (NITI) [RM= 3.1 (1.2-8.1), p= 0.01] CONCLUSIONES: Los pacientes con la infección por el VIH que reciben terapia antirretroviral (TAR) tienen un riesgo aumentado de presentar dislipidemia. A diferencia de lo que informan la mayor parte las publicaciones, las alteraciones de los lípidos se asociaron con más frecuencia al uso de NITI, por lo que se concluye que la patogenia de estas alteraciones no es única y que resulta probable la existencia de un efecto sinérgico entre las distintas familias de fármacos antirretrovíricos y que otros factores del huésped participen en la génesis de estas alteraciones. OBJECTIVE: To determine the prevalence of secondary effects on lipid metabolism as a result of highly active antiretroviral therapy (HAART), as well as the impact of different types of antiretroviral regimens on lipids and glucose in a group of patients in Yucatan, Mexico MATERIAL AND METHODS: A cross-sectional study was conducted. A questionnaire created for this study was administered to each patient and total cholesterol, triglycerides and fasting glucose values were determined. The presence of hyperlipidemia and alterations in glucose were determined as well as their relation to the epidemiological variables obtained from the questionnaire RESULTS: A total of 211 subjects were studied [36 (17%) of which were women and 175 (83%) men]. Ninety-two patients (44%) were found to have hyperlipidemia. Of these, 43 (20%) had hypercholesterolemia (HC) and 82 (39%) hypertriglyceridaemia (HT). The presence of combined HC and HT was observed in 30 (14%) patients. Nineteen (9%) patients had alterations in glucose, six (3%) diabetes mellitus and 13 (6%) impaired glucose tolerance. The variables associated with the presence of hyperlipidemia were: levels of lymphocytes CD4>350 cells/µl (OR= 2.79 1.08-7.27, p= 0.03), male gender (OR= 3.6 1.4-9.12, p= 0.006) and the use of nucleoside-reverse transcriptase inhibitors (NRTI) (OR= 3.1 1.2-8.1, p=0.01) CONCLUSIONS: Patients with HIV infection who receive HAART have an increased risk of presenting hyperlipidemia. In this group of patients the presence of hyperlipidemia and impaired glucose tolerance was significant. Unlike what has been indicated in most published reports, the alterations of lipids were associated more frequently with INTR use, for which it is concluded that the pathogeny of these alterations is not unique, that it is probable that concurrent effects exist between different antiretroviral drug families and that other host factors are involved in the pathogenic mechanism of these alterations.